Pharmaceutical compounds

1. A compound or a salt thereof having the following general formula (I):

A—B—C—N(O) 2   (I)

wherein:

A =R-T 1 -, wherein

R is the radical of a drug having the formula R—T 1 —Z or R—T 1 —OZ, wherein

T 1 is (CO), O, S, N or NR 1c wherein

R 1c is H, C 1 -C 5 alkyl or a free valance,

Z is H or C 1 -C 5 alky; and

the drug having the formula R-T 1 -Z or R-T 1 -OZ is selected from the following classes:

anti-inflammatory drugs: acetylsalicylic acid, 5-aminoacetylsalicylic acid, carprofen, diclofenac sodium salt, diflunisal, etodolac, flufenamic acid, flunixin, flurbiprofen, ibuprofen, indomethacin, indoprofen, ketoprofen, ketorolac, lornoxicam, loxoprofen, meclofenamic acid, mefenamlc acid, meloxicam, mesalamine, naproxen, niflumic acid, olsalazine, piroxicam, salsalate, sulindac, suprofen, tenoxicam, tiaprofenic acid, tolfenamic acid, tolmetin, and zomepirac;

analgesic drugs: acetaminophen, acetylsalicylsallcylic acid, benoxaprofen, buprenorphine, butorphanol, capsaicin, diacereine, dihydrocodeine, ethylmorphine, eugenol, phenylbutazone, meptazinol, morphine, nalbuphine, pentazocine, thiorphan, tramadol, actarit;

bronchodilators drugs: albuterol, carbuterol, clenbuterol, dyphylline, etofylline, fenoterol, metaproterenol, pirbuterol, salmeterol, and terbutaline;

antihistaminic drugs: cetirizine, levocabastine, and terfenadine;

ACE-inhibitors: captopril, enalapril, lisinopril, ramipril;

beta blockers: alprenolol, atenolol, bupranolol, labetalol, metipranolol, metoprolol, pindolol, propranolol, timolol;

antithrombotic and vasoactive drugs: acetorfan, argatroban, clopidogrel, dalteparin, dipyridamole, enoxaparin, heparin, iloprost, midodrine, ozagrel, phenylpropanolamine, trifusal;

antidiabetic drugs: nicotinamide, tolrestat;

antiulcer drugs: cimetidine, omeprazole and pantoprazole;

antiviral drugs: acyclovir, famciclovir, ganciclovir, penciclovir, ribavirin, vidarabine, zidovudine;

B =T B -X 2 -T Bl -wherein

T B and T Bl are equal or different,

T B is (CO) when T 1 is O, S, N, or NR 1C , wherein R 1C is as above defined, or

T B is O, S, N, or NR 1C , wherein R 1C is as above defined, when T 1 is (CO);

T Bl is (CO), O, S, N, or NR 1C , wherein R 1C is as above defined;

X 2 is a bivalent bridging group having the formula Z′-T B -X 2 -T Bl -Z″, in which Z′, Z″ are independently H or OH, T B , X 2 , and T Bl are as above defined, and Z′- B -X 2 -T Bl -Z″ is selected from the following aminoacids: L-carnosine (Cl), penicillamine (CV), N-acetylpenicillamine (CVI), cysteine (CVII), N-acetylcysteine (CVIII):

C is a bivalent radical -T c -Y— wherein

T C is (CO) when T Bl is O, S, or NR 1C ,

T C is O, S, or NR 1C when T B1 is (CO), R 1C being as above defined,

Y is a linear or branched C 1 -C 20 alkylenoxy group.

2. The compound or salt thereof according to claim 1 , wherein Y is an C 1 -C 6 linear or branched alkylenoxy group.

3. A pharmaceutical composition comprising a compound or salt according to claim 1 and a pharmaceutically acceptable carrier.

4. A method for treating oxidative stress dysfunction, the method comprising administering a therapeutically effective amount of the compound or salt according to claim 1 to a patient in need thereof.